Because of their similar hydrolytic activities, AChE/BChE overexpression around plaques can lead to reduced neurotransmitter levels, and thus it is thought that AChE/BChE inhibition may alleviate some AD symptoms by prolonging the half lives of neurotransmitters. Here, BCHE is linked to Alzheimer disease.